Afya Limited (AFYA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with significant revenue and EBITDA growth, increased medical seats, and a share repurchase program. The Q&A session reveals some uncertainties, such as the impact of new tax reforms and unclear guidance for 2026. However, the company's strategic capital allocation and expected tuition growth contribute positively. Given the market cap of approximately $1.5 billion, the positive sentiment is likely to result in a moderate stock price increase in the range of 2% to 8%.
Key Financial Performance
Revenue for the 9-month period BRL 2,784 million, a 13% increase year-over-year. The growth was driven by higher tickets in medicine courses, the maturation of medical school seats, and the acquisition of FUNIC.
Adjusted EBITDA for the 9-month period BRL 1,292 million, a 19% increase year-over-year. The adjusted EBITDA margin reached 46.4%, an increase of 200 basis points, driven by higher gross margins in the Undergraduate and Continuing Education segments, restructuring initiatives, and improved efficiency in selling, general, and administrative expenses.
Cash flow from operating activities for the 9-month period BRL 1,292 million, an 11% increase year-over-year, with a cash conversion ratio of 101.5%. This reflects strong operational performance.
Net Income for the 9-month period BRL 593 million, a 20% increase year-over-year. This growth was due to stronger operational performance and the recognition of deferred tax assets, partially offset by additional taxation provisions related to the OECD's Pillar Two global minimum tax effects.
Basic EPS for the 9-month period BRL 6.40, a 20% increase year-over-year, reflecting stronger operational performance.
Revenue from Continuing Education segment for the 9-month period BRL 208 million, an 11% increase year-over-year. This growth was driven by an increase in the average ticket per student and a 65% increase in B2B revenue.
Revenue from Medical Practice Solutions segment for the 9-month period BRL 128 million, a 9% increase year-over-year. This growth was driven by an expansion in active payers in clinical management and a more favorable product mix.
Net average ticket for medical school (excluding acquisitions) BRL 9,141, a 3.4% increase year-over-year, driven by higher tickets in medicine courses.
Number of undergraduate medical students More than 25,000 students, a 6% increase year-over-year, supported by the expansion of medical school seats.
Net debt as of the end of the third quarter of 2025 BRL 1,342 million, a reduction of BRL 473 million compared to the end of 2024. This reduction was achieved despite the acquisition of FUNIC and shareholder returns through dividends and share repurchases.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Medical Practice Solutions revenue growth: Revenue grew over 9% year-over-year, reaching BRL 128 million in the 9-month period.
Continuing Education revenue growth: Revenue increased by 11% year-over-year, reaching BRL 208 million.
Undergraduate medical education expansion: Approved medical seats increased to 3,753, with 100 new seats in Afya Braganca. Undergraduate medical students grew by 6% year-over-year, reaching over 25,000 students.
Ecosystem expansion: Afya's ecosystem reached 304,000 active users, reflecting strong engagement among physicians and medical students across Brazil.
B2B revenue growth in Continuing Education: B2B revenues increased by 65% year-over-year in the Continuing Education segment.
Adjusted EBITDA growth: Adjusted EBITDA grew by 19% year-over-year, reaching BRL 1,292 million, with a margin increase of 200 basis points to 46.4%.
Cash flow from operating activities: Cash flow increased by 11% year-over-year, reaching BRL 1,292 million, with a cash conversion ratio of 101.5%.
Net income growth: Net income grew by 20% year-over-year, reaching BRL 593 million.
ESG initiatives: Delivered 700,000 free healthcare consultations, exceeding 2025 targets, and launched Instituto Afya to focus on sustainability and social impact.
Liability management: Issued BRL 1.5 billion in commercial notes to redeem debentures and repurchase preferred shares, extending debt duration to 3.2 years and maintaining a low cost of debt.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces potential risks related to regulatory approvals, as highlighted by the need for authorization for medical school seat expansions. Any delays or denials in regulatory approvals could impact growth plans.
Economic Uncertainties: The company operates in Brazil, where economic conditions can be volatile. Changes in economic policies, inflation, or currency fluctuations could adversely affect financial performance.
Operational Challenges in Medical Practice Solutions: The Medical Practice Solutions segment saw a 2% decrease in active payers and a decline in monthly active users, which could indicate challenges in user retention or market competition.
Taxation Risks: The recognition of additional taxation provisions related to the OECD's Pillar Two global minimum tax effects could increase the company's tax burden, impacting net income.
Debt Management Risks: While the company has extended its debt duration and maintained a low cost of debt, any changes in interest rates or financial market conditions could affect its ability to manage debt effectively.
Dependency on Medical Education Segment: A significant portion of revenue (86%) is derived from medical school students. Over-reliance on this segment could pose risks if there are changes in market demand or regulatory policies affecting medical education.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expansion of Medical School Seats: Afya plans to expand its medical school seats, with 100 new seats approved in Afya Braganca, bringing the total to 3,753 seats. This represents a 4% increase in approved medical seats as of the third quarter of 2025.
Continuing Education Growth: Afya plans to expand its Continuing Education segment with 5 new operating units in 2025. The segment is expected to see further growth in B2B revenues, which increased by 65% in the 9-month period of 2025.
Medical Practice Solutions Growth: Afya anticipates continued growth in its Medical Practice Solutions segment, driven by an expansion in active payers in clinical management and a favorable product mix. Revenue in this segment grew by 9% year-over-year in the 9-month period of 2025.
Financial Guidance: Afya expects to maintain strong financial performance, with adjusted EBITDA margins projected to remain high due to gross margin expansion in the Undergraduate and Continuing Education segments, as well as improved efficiency in selling, general, and administrative expenses.
Liability Management and Financial Flexibility: Afya has strengthened its financial position through liability management, including the issuance of commercial notes totaling BRL 1.5 billion. This has extended gross debt duration to 3.2 years and maintained a low cost of debt at 106% of the CDI, supporting long-term value creation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: Afya's net debt variation reflects returns to shareholders through dividends.
Shares Repurchase: Afya repurchased 150,000 Series A preferred shares held by SoftBank as part of its liability management strategy.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's current understanding of the effective tax rate and its future assumptions?
A:The effective tax rate for the 9-month period was 9.7%, up from 5.1% last year, due to provisions for the Pillar Two taxations implemented in Brazil for 2025. These taxes will be disbursed in July 2026. From 2026 onwards, the effective tax rate is expected to converge to the minimum taxation of 15% unless changes in legislation occur.
Q:What is the company's capital allocation strategy going forward?
A:The company raised new debt through commercial notes and prepaid debentures, repurchasing preferred shares from SoftBank. They are evaluating options such as M&A, buybacks, or dividend payments to maximize shareholder value.
Q:Are there any strategies being evaluated in light of the new tax reform and its impact on foreign players and investors?
A:The company is analyzing opportunities in medical school assets and plans to maintain around 200 seats per year. They will combine buyback programs and dividend payments, considering the 10% additional cost and market conditions.
Q:What are the trends observed in the 2026 intake cycle?
A:It is early to provide detailed trends, but the tuition for 2026 is expected to increase by 5% to 5.2% over 2025.
Q:Should we expect any mix effect next year or will the average ticket converge to the 5% growth mentioned?
A:The average ticket is expected to grow by 5% to 5.2%. The penetration of FIES among medical students is expected to remain stable at 17%-18%, but it is too early to assess the portfolio mix.
Q:Are there any changes in how applicants perceive the attractiveness of a medical career?
A:The demand for medical careers remains consistent with last year, with no substantial differences observed.
Q:What caused the sequential increase in gross margins for Medical Practice Solutions?
A:The 7-point sequential increase in gross margins was due to cost management and seasonality. Compared to the same quarter last year, margins were 2% lower.
Q:Why has there been a sequential loss of subscribers in the clinical decision software?
A:The loss of subscribers was due to a price increase in the Whitebook solution, which led to a reduction in freemium users. The company is reviewing features to resume growth. Meanwhile, iClinic is experiencing accelerated penetration.
Q:What is the expected time frame for the ramp-up of FUNIC and its margins?
A:FUNIC is in its first year of operation with low margins due to initial implementation costs. Margins are expected to scale to 50%-60% within 2-3 years as the number of students increases.
Q:Is there room for further margin expansion in the consolidated EBITDA margin?
A:The company has achieved significant margin expansion over the past two years through efficiency gains, zero-cost budgeting, and segment optimization. Further expansion will depend on continued efficiency improvements.
Q:Why did the number of students in the Residency Journey drop by over 30%?
A:The drop was due to combining the mentoria and residence prep products into a single offering, which reduced the count of unique subscribers but did not significantly impact revenue.
Q:Review of Unclear Management Responses
A:Management avoided providing detailed trends for the 2026 intake cycle, stating it was too early to assess. Similarly, they did not provide clarity on the mix effect of FIES on the average ticket for next year, citing it was too early to evaluate.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Award company
BP revenue
BRL month
BRL update
Braganca number
Braganca seat
Brazil result
Brazil row
Brazil th
Brazil unit
CEO CFO
CEO Renata
Continuing Education
Development Goal
ESG Valor
ESG practice
ESG term
Economico Valor
Education segment
FUNIC addition
Goal number
IPO profitability
Income trend
Instituto chapter
Medical Practice
Practice Solutions
commitment
consultation
month period
period BRL
period increase
revenue period
seat Braganca
sustainability
AFYA Transcript
Afya Limited (AFYA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call reveals strong financial performance with significant revenue growth, increased net income, and improved operating margins. These positive financial metrics suggest a healthy business outlook. The lack of discussion on operational updates, strategic initiatives, risk, and return may limit the potential upside, but the strong financial results should still lead to a positive stock price movement in the short term.
Afya Limited (AFYA) Q4 2025 Earnings Call Transcript
Positive3-13
Afya's earnings call highlights strong financial performance with a 15% revenue increase, driven by strategic expansions and acquisitions. EBITDA and net income have also risen significantly, indicating operational efficiency. Despite acknowledging potential risks, the company's proactive financial management and growth in key segments suggest a positive outlook. Given the market cap of approximately $1.5 billion, the positive financial results and strategic growth initiatives are likely to result in a moderate stock price increase, placing the sentiment in the 'Positive' category (2% to 8%).
Afya Limited (AFYA) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call summary indicates strong financial performance with significant revenue and EBITDA growth, increased medical seats, and a share repurchase program. The Q&A session reveals some uncertainties, such as the impact of new tax reforms and unclear guidance for 2026. However, the company's strategic capital allocation and expected tuition growth contribute positively. Given the market cap of approximately $1.5 billion, the positive sentiment is likely to result in a moderate stock price increase in the range of 2% to 8%.
Afya Limited (AFYA) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call summary and Q&A highlight strong financial performance with net income and EBITDA growth, debt reduction, and a positive outlook on shareholder returns via a buyback program. Despite a conservative stance on guidance and challenges with medical ticket growth, the company maintains strong operational metrics and strategic initiatives in education and medical segments. The market cap suggests moderate sensitivity to positive news, leading to a positive stock price prediction.
AFYA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
